title: A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer.
abstract: OBJECTIVE
  To investigate the activity of carboplatin and cetuximab in NSCLC.
  
  
  METHODS
  This was a single arm, multicenter phase II trial, and the primary objective was response rate.
  
  
  RESULTS
  The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45).
  
  
  CONCLUSIONS
  The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.
authors.affiliation: Multidisciplinary Thoracic Oncology Program at Lineberger Comprehensive Cancer Center at the University of North Carolina, Physicians Office Building, 3rd Floor 170 Manning Drive, Cb 7305, Chapel Hill, NC 27599-7305, USA. Thomas_Stinchcombe@med.unc.edu
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Stinchcombe
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Bradford
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Hensing
authors.forename: Renato V
authors.initials: RV
authors.lastname: LaRocca
authors.forename: Mansoor
authors.initials: M
authors.lastname: Saleh
authors.forename: Tracey
authors.initials: T
authors.lastname: Evans
authors.forename: Kamal
authors.initials: K
authors.lastname: Bakri
authors.forename: Mark A
authors.initials: MA
authors.lastname: Socinski
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000068818:Cetuximab; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016190:Carboplatin; D000068818:Cetuximab